What is the core difference between retatrutide and semaglutide?
The cleanest way to think about it is how many receptors each molecule activates. Semaglutide — the compound sold as Ozempic, Wegovy, and Rybelsus — is a single GLP-1 receptor agonist. Retatrutide is a triple agonist: it activates the GLP-1 receptor plus two more, GIP and glucagon.
That third target, the glucagon receptor, is the headline. Glucagon-receptor activity is linked to increased energy expenditure and reduced liver fat, which is the mechanistic rationale for the larger weight-loss figures retatrutide produced in early trials. Semaglutide leans entirely on GLP-1 — appetite suppression, slowed gastric emptying, and glucose-dependent insulin release.
The difference that matters most today, though, is regulatory: semaglutide is an approved medicine with years of real-world data, while retatrutide is still an investigational compound being studied in clinical trials.
Which produced more weight loss in clinical trials?
In its phase 2 obesity trial, retatrutide at the 12 mg dose produced a mean weight reduction of roughly 24.2% at 48 weeks — among the largest figures reported for any weight-loss drug. Semaglutide, in the phase 3 STEP 1 trial, produced roughly 14.9% at the 2.4 mg dose over 68 weeks.
It is important not to over-read this. The two figures came from different trials, with different durations, dose schedules, and patient populations — they were never compared head-to-head. A larger phase 2 number does not guarantee superiority once retatrutide completes phase 3, where efficacy often moderates as the study population broadens. Semaglutide's number, by contrast, comes from a completed pivotal trial that supported an FDA approval.
How do the side effects compare?
Both drugs are dominated by gastrointestinal side effects — nausea, diarrhea, vomiting, and constipation — because both engage the GLP-1 system. In both, these effects are dose-dependent and tend to ease as the dose is escalated gradually.
Retatrutide trials additionally reported dose-dependent increases in heart rate that peaked around 24 weeks and then declined. Its long-term safety record is, by definition, thinner: semaglutide has been prescribed to millions and carries a large post-market safety database, while retatrutide's safety profile is still being characterized in ongoing trials. That asymmetry in evidence is itself a meaningful difference.
Is retatrutide available, and is it legal?
Retatrutide is not approved by the FDA or any major regulator. The only lawful way to receive it is by enrolling in a clinical trial. Material sold online as "research" retatrutide is explicitly labeled not for human use and sits outside the regulated supply chain — its identity, purity, and sterility are unverified.
Semaglutide, by contrast, is available by prescription as Ozempic, Wegovy, or Rybelsus through licensed pharmacies. If weight management or glycemic control is the goal today, semaglutide is the option with an approval, a known supply chain, and an established safety record. Any GLP-1 decision should be made with a licensed clinician.
Tracking either compound on PeptidePanel
Whichever agent a clinician prescribes, the day-to-day work is the same: log doses, watch the biomarkers that matter (HbA1c, lipids, liver enzymes, weight trend), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, or prescribe any compound. It is a monitoring tool for protocols a qualified prescriber has put you on.